Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Greater Cannabis CoGCAN 30 EV-to-EBITDA is -2.12 as of Aug. 11, 2026. GuruFocus rates GCAN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 736 Drug Manufacturers companies, Greater Cannabis Co ranks worse than 135869.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Greater Cannabis Co's enterprise value is $0.56 Mil.
Greater Cannabis Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.26 Mil. Therefore, Greater Cannabis Co's EV-to-EBITDA for today is -2.12.
The historical rank and industry rank for Greater Cannabis Co's EV-to-EBITDA or its related term are showing as below:
GCAN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.5 Med: -1.47 Max: 1.75
Current: -2.12
During the past 10 years, the highest EV-to-EBITDA of Greater Cannabis Co was 1.75. The lowest was -4.50. And the median was -1.47.
GCAN's EV-to-EBITDA is ranked worse than 100% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.185
vs GCAN: -2.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Greater Cannabis Co (OTCPK:GCAN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Greater Cannabis Co's PE Ratio (TTM) for today is calculated as:
Greater Cannabis Co's share price for today is $0.28.
Greater Cannabis Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Greater Cannabis Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Greater Cannabis Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greater Cannabis Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Greater Cannabis Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Greater Cannabis Co's EV-to-EBITDA falls into.
Greater Cannabis Co's current Enterprise Value is $0.56 Mil.
Greater Cannabis Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greater Cannabis Co (GCAN) has a EV-to-EBITDA of -2.12 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Greater Cannabis Co. According to the industry distribution chart, Greater Cannabis Co ranks #999999 out of 736 companies in the Drug Manufacturers industry.
Is Greater Cannabis Co's EV-to-EBITDA too high?
Greater Cannabis Co's current EV-to-EBITDA is -2.12. Based on the distribution chart, Greater Cannabis Co ranks #999999 out of 736 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Greater Cannabis Co has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Greater Cannabis Co's EV-to-EBITDA compare to STEK and KAYS?
According to the Drug Manufacturers industry distribution chart, Greater Cannabis Co ranks #999999 out of 736 companies for EV-to-EBITDA. This places Greater Cannabis Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.19, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Greater Cannabis Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greater Cannabis Co's current EV-to-EBITDA is -2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greater Cannabis Co stock overvalued right now?
Greater Cannabis Co (GCAN) has a current EV-to-EBITDA of -2.12. The current EV-to-EBITDA is -2.12. Greater Cannabis Co's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Greater Cannabis Co (GCAN), the current EV-to-EBITDA is -2.12 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Greater Cannabis Co Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a pharma-grade therapeutic that reduces disruptive symptoms in patients suffering from neuropsychiatric disorders without the side effects of existing medications. The company is focused on developing new formulations around cannabinoid therapeutics.
30GF Score
Get the complete analysis for GCAN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GCAN has been successfully added to your 
